Imunon announces withdrawal of Form S-1 Registration Statement
Imunon (IMNN) announced that it has filed a request for withdrawal with the SEC of the company's Registration Statement on Form S-1 (No. 333-286403), as amended, originally filed on April 4, 2025, as the company no longer intends to pursue a public offering under the Registration Statement at this time. The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the Registration Statement.
Confident Investing Starts Here:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
IFF Unveils Game-Changing Outlook on GLP-1 Consumers
NEW YORK--(BUSINESS WIRE)-- IFF (NYSE: IFF), a global leader in food, beverage, and health and wellness, has released a new report highlighting how the rapidly growing GLP-1 consumer market is reshaping the sensory experience and nutritional needs associated with eating and drinking. The report outlines how food and beverage manufacturers can better support this emerging consumer segment with products that align with their evolving preferences. 'IFF is empowering our customers to lead the next wave of food and beverage innovations beyond traditional formulations, including helping GLP-1 consumers have choices they desire,' said Erik Fyrwald, IFF CEO. 'We aim to bring back the joy of eating and drinking by offering more healthy, great-tasting nutrition choices for all consumer segments, including GLP-1 users.' Disconnect on three levels Despite the rapid rise in GLP-1 medication use, most food and beverage products fall short of meeting the needs of these consumers—or aligning with how they now experience food. IFF has identified a disconnect on three key levels: Nutritional: GLP-1 users are eating less but require more from every bite and sip. They need nutrient-dense, smaller portions that efficiently deliver protein, fiber and hydration—without overwhelming flavors. Sensory: Eighty-five percent of GLP-1 consumers report significant changes in their food and beverage preferences. Common aversions include fatty foods, sweets, deli meats, coffee and alcohol. Dry, sticky or dense textures are also frequently rejected. Emotional: Many consumers are navigating a changed relationship with food—one that may involve a sense of loss, social disruption and a search for new meaning in nourishment. Understanding the GLP-1 Consumer Personas IFF is in the early stages of exploring GLP-1 consumer segmentation to help brands move beyond a one-size-fits-all approach toward one grounded in empathy, specificity and long-term relevance. The company's latest outlook introduces key consumer personas, which are expected to evolve over time: Health Hacker Holly: Proactive, data-driven and focused on long-term wellness, she views GLP-1 as part of a broader bio-optimization journey. She seeks functional benefits in formats such as protein bars, smoothies and enriched hydration blends, prioritizing high-quality protein, added fiber and digestive support. Remedy Reacher Ron: Often managing chronic conditions such as diabetes, he uses GLP-1 to reclaim his health and sees food as both medicine and maintenance. He looks for fortified snacks and gut-friendly options aligned with medical guidance, favoring meal kits and low-glycemic shakes. Glow Getter Gail: Transformation-minded and focused on lifestyle and self-image, she wants food that aligns with her goals and identity—aspirational yet approachable, with 'glow-up' appeal. She seeks portion-conscious indulgences, beauty-boosting nutrition and enjoyable flavors in formats such as smoothies, functional waters and shareable treats. The outlook also outlines how the food and beverage needs of each GLP-1 persona evolve over time. In the initial treatment phase, consumers need support managing smaller portion sizes and medication side effects. The transitional phase focuses on preventing regression, requiring flexible serving sizes and flavor intensity options that adapt to changing cravings. In the 'forever' phase, consumers seek to sustain their new routines with habit-forming formats for daily use, nutritional fortification and pre-portioned, high-satiety foods. Driving Empathy-Powered Innovation IFF has introduced a comprehensive framework to support food and beverage manufacturers in addressing the complex sensory and nutritional needs of GLP-1 consumers. The framework is designed to guide both the reformulation of existing products and the development of new offerings, tackling challenges such as muscle mass maintenance, satiety, digestive support and sensory preferences. To demonstrate practical applications, IFF has developed a suite of AI-refined, consumer-tested product concepts that show how manufacturers can optimize their portfolios for this rapidly expanding market. For more information, download the 2025 GLP-1 Consumer Opportunity Outlook here to uncover more insights and consumer-tested concepts. Welcome to IFF At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at X (Twitter), Facebook, Instagram, and LinkedIn. ©2025 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.
Yahoo
2 hours ago
- Yahoo
Cepheid Receives Health Canada Licence for Xpert® HIV-1 Viral Load XC
Next-Generation Molecular Test for Monitoring Viral Load and HIV-1 Infection SUNNYVALE, Calif., June 4, 2025 /CNW/ -- Cepheid today announced that Health Canada has issued Cepheid a medical device licence for Xpert® HIV-1 Viral Load XC, a next-generation extended-coverage (XC) test intended to aid in assessing HIV viral load levels, which are used to monitor effectiveness of antiretroviral treatment. Xpert® HIV-1 Viral Load XC dual target test provides extended strain coverage ensuring a high level of performance with a simple workflow to improve patient access to the standard of care and help achieve UNAIDS HIV targets by 2030.1 "Xpert® HIV-1 Viral Load XC leverages dual target technology to improve detection while maintaining the flexibility to be performed on-demand in as little as 90 minutes." said Vitor Rocha, President of Cepheid. "Access to the test can enhance patient care, as measurement of HIV viral load informs treatment plans while fast results enable earlier interventions with counseling and therapy." The test is designed for use on any of Cepheid's GeneXpert® Systems which provide simple, reference lab quality PCR testing on location in laboratory environments at medical centers and hospitals or in community health clinics and physician offices. Xpert® HIV-1 Viral Load XC will begin shipping to customers in Canada in June 2025. Visit for more information. Malisa et al 2023 Nature Scientifc Reports | (2023) 13:4578https:// About CepheidBased in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company that is an operating company within Danaher Corporation's Diagnostics platform. Cepheid is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit IVD. In Vitro Diagnostic Medical Device. May not be available in all countries For Cepheid Media Inquiries:Darwa SOURCE Cepheid View original content to download multimedia: Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Business Wire
4 hours ago
- Business Wire
Voyager Closes $200 Million Credit Facility
DENVER--(BUSINESS WIRE)--Voyager Technologies Inc. (Voyager), a global leader in defense technology and space solutions, closed a $200 million syndicated credit facility led by J.P. Morgan. Net proceeds allow Voyager to continue to scale its defense, national security and space solutions businesses in support of customer demand. 'Our credit facility, led by J.P. Morgan and other well-known financial institutions, further bolsters our liquidity and demonstrates Voyager's strong financial position in the defense and space technology sectors,' said Dylan Taylor, chairman and chief executive officer, Voyager Technologies. Effectiveness of the commitments and availability of funds under the syndicated credit facility are subject to the terms of the credit agreement. About Voyager: Voyager Technologies, Inc. (Voyager) is a defense and space technology company committed to advancing and delivering transformative, mission-critical solutions. By tackling the most complex challenges, Voyager aims to unlock new frontiers for human progress, fortify national security, and protect critical assets from ground to space. For more information visit: Cautionary Statement Concerning Forward-Looking Statements Certain statements contained in this press release, including statements relating to the expected benefits from the syndicated credit facility, Voyager's access to funds thereunder and Voyager's mission statement and growth strategy, may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Voyager intends for all such forward-looking statements to be covered by the applicable safe harbor provisions for forward-looking statements contained in those acts. Such forward-looking statements can generally be identified by Voyager's use of forward-looking terminology such as 'may,' 'will,' 'expect,' 'intend,' 'anticipate,' 'estimate,' 'believe,' 'continue,' 'seek,' 'objective,' 'goal,' 'strategy,' 'plan,' 'focus,' 'priority,' 'should,' 'could,' 'potential,' 'possible,' 'look forward,' 'optimistic,' or other similar words. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Such statements are subject to certain risks and uncertainties, including, but not limited to those discussed in the section entitled 'Risk Factors' in Voyager's Registration Statement on Form S-1/A filed with the SEC on June 2, 2025, as any such factors may be updated from time to time in Voyager's other filings with the SEC. Such risks and uncertainties could cause actual results to differ materially from those projected or such statements are not intended to be a guarantee of Voyager's performance in future periods. Except as required by law, Voyager does not undertake any obligation to update or revise any forward-looking statements contained in this press release.
